{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T06:19:43Z","timestamp":1783664383206,"version":"3.55.0"},"reference-count":58,"publisher":"MDPI AG","issue":"20","license":[{"start":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T00:00:00Z","timestamp":1665446400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Merck","award":["P30CA04790"],"award-info":[{"award-number":["P30CA04790"]}]},{"name":"National Cancer Institute Cancer Center Support","award":["P30CA04790"],"award-info":[{"award-number":["P30CA04790"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>We sought to develop a sentinel lymph node gene expression signature score predictive of disease recurrence in patients with cutaneous melanoma. Gene expression profiling was performed on SLN biopsies using U133A 2.0 Affymetrix gene chips. The top 25 genes associated with recurrence-free survival (RFS) were selected and a penalized regression function was used to select 12 genes with a non-zero coefficient. A proportional hazards regression model was used to evaluate the association between clinical covariates, gene signature score, and RFS. Among the 45 patients evaluated, 23 (51%) had a positive SLN. Twenty-one (46.7%) patients developed disease recurrence. For the top 25 differentially expressed genes (DEG), 12 non-zero penalized coefficients were estimated (CLGN, C1QTNF3, ADORA3, ARHGAP8, DCTN1, ASPSCR1, CHRFAM7A, ZNF223, PDE6G, CXCL3, HEXIM1, HLA-DRB). This 12-gene signature score was significantly associated with RFS (p &lt; 0.0001) and produced a bootstrap C index of 0.888. In univariate analysis, Breslow thickness, presence of primary tumor ulceration, SLN positivity were each significantly associated with RFS. After simultaneously adjusting for these prognostic factors in relation to the gene signature, the 12-gene score remained a significant independent predictor for RFS (p &lt; 0.0001). This SLN 12-gene signature risk score is associated with melanoma recurrence regardless of SLN status and may be used as a prognostic factor for RFS.<\/jats:p>","DOI":"10.3390\/cancers14204973","type":"journal-article","created":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T22:18:13Z","timestamp":1665526693000},"page":"4973","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Sentinel Lymph Node Gene Expression Signature Predicts Recurrence-Free Survival in Cutaneous Melanoma"],"prefix":"10.3390","volume":"14","author":[{"given":"Lilit","family":"Karapetyan","sequence":"first","affiliation":[{"name":"Department of Cutaneous Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Gooding","sequence":"additional","affiliation":[{"name":"Hillman Cancer Center, Biostatistics Facility, Pittsburgh, PA 15213, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aofei","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Medicine, Brigham and Women\u2019s Hospital and Dana Farber Cancer Institute, Boston, MA 02215, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Knight","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of General Internal Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0068-5201","authenticated-orcid":false,"given":"Hassan M.","family":"Abushukair","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Jordan University of Science and Technology, Irbid 22110, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4847-3718","authenticated-orcid":false,"given":"Danielle","family":"Vargas De Stefano","sequence":"additional","affiliation":[{"name":"Department of Pathology, Division of Pediatric Pathology, UPMC Children\u2019s Hospital of Pittsburgh, Pittsburgh, PA 15224, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy","family":"Sander","sequence":"additional","affiliation":[{"name":"UPMC Hillman Cancer Center, Pittsburgh, PA 15213, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arivarasan","family":"Karunamurthy","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA"},{"name":"Departments of Dermatology and Pathology, Divisions of Dermatopathology and Molecular Genetic Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Panelli","sequence":"additional","affiliation":[{"name":"UPMC Hillman Cancer Center, Pittsburgh, PA 15213, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter J.","family":"Storkus","sequence":"additional","affiliation":[{"name":"Departments of Dermatology, Immunology, Pathology and Bioengineering, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad A.","family":"Tarhini","sequence":"additional","affiliation":[{"name":"Departments of Cutaneous Oncology and Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3570-4476","authenticated-orcid":false,"given":"John M.","family":"Kirkwood","sequence":"additional","affiliation":[{"name":"UPMC Hillman Cancer Center, Pittsburgh, PA 15213, USA"},{"name":"Department of Medicine, Division of Hematology\/Oncology; University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh, PA 15213, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,10,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"472","DOI":"10.3322\/caac.21409","article-title":"Melanoma staging: Evidence-based changes in the American Joint Committee on cancer eighth edition cancer staging manual","volume":"67","author":"Gershenwald","year":"2017","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1158\/1078-0432.107.11.1","article-title":"Quantitative analysis of melanoma-induced cytokine-mediated immunosuppression in melanoma sentinel nodes","volume":"11","author":"Lee","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s00262-011-0982-x","article-title":"Molecular analysis of melanoma-induced sentinel lymph node immune dysfunction","volume":"60","author":"Lee","year":"2011","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1056\/NEJMoa060992","article-title":"Sentinel-node biopsy or nodal observation in melanoma","volume":"355","author":"Morton","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1001\/archsurg.1992.01420040034005","article-title":"Technical details of intraoperative lymphatic mapping for early stage melanoma","volume":"127","author":"Morton","year":"1992","journal-title":"Arch. Surg."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"538","DOI":"10.7150\/jca.2.538","article-title":"Malignant melanoma in the elderly: Different regional disease and poorer prognosis","volume":"2","author":"Macdonald","year":"2011","journal-title":"J. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1158\/2159-8290.CD-18-0168","article-title":"Age-related changes in HAPLN1 increase lymphatic permeability and affect routes of melanoma metastasis","volume":"9","author":"Ecker","year":"2019","journal-title":"Cancer Discov."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1245\/ASO.2003.06.007","article-title":"Sentinel lymph node biopsy for head and neck melanomas","volume":"10","author":"Chao","year":"2003","journal-title":"Ann. Surg. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.1245\/s10434-013-2977-7","article-title":"Is head and neck melanoma different from trunk and extremity melanomas with respect to sentinel lymph node status and clinical outcome?","volume":"20","author":"Fadaki","year":"2013","journal-title":"Ann. Surg. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/nri1919","article-title":"Tumour\u2014Induced immune modulation of sentinel lymph nodes","volume":"6","author":"Cochran","year":"2006","journal-title":"Nat. Rev. Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e1026504","DOI":"10.1080\/2162402X.2015.1026504","article-title":"Evidence of Th2 polarization of the sentinel lymph node (SLN) in melanoma","volume":"4","author":"Grotz","year":"2015","journal-title":"Oncoimmunology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1245\/s10434-012-2826-0","article-title":"Sentinel node biopsy in thin and thick melanoma","volume":"20","author":"Mozzillo","year":"2013","journal-title":"Ann. Surg. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S1470-2045(15)70122-1","article-title":"Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): A randomised, double-blind, phase 3 trial","volume":"16","author":"Eggermont","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","article-title":"Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma","volume":"377","author":"Long","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1016\/S0140-6736(22)00562-1","article-title":"Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): A randomised, double-blind, phase 3 trial","volume":"399","author":"Luke","year":"2021","journal-title":"Lancet"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1097\/CMR.0000000000000383","article-title":"A unique gene expression signature is significantly differentially expressed in tumor-positive or tumor-negative sentinel lymph nodes in patients with melanoma","volume":"27","author":"Tarhini","year":"2017","journal-title":"Melanoma Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v033.i01","article-title":"Regularization paths for generalized linear models via coordinate descent","volume":"33","author":"Friedman","year":"2010","journal-title":"J. Stat. Softw."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"W216","DOI":"10.1093\/nar\/gkac194","article-title":"DAVID: A web server for functional enrichment analysis and functional annotation of gene lists (2021 update)","volume":"50","author":"Sherman","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1146\/annurev.cellbio.20.012103.094623","article-title":"Dynactin","volume":"20","author":"Schroer","year":"2004","journal-title":"Annu. Rev. Cell Dev. Biol."},{"key":"ref_21","first-page":"3752","article-title":"Prognostic value of dynactin mRNA expression in cutaneous melanoma","volume":"24","author":"Wang","year":"2018","journal-title":"Med. Sci. Monit. Int. Med. J. Exp. Clin. Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"8149","DOI":"10.2147\/IJGM.S338135","article-title":"Prediction of survival outcome in lower-grade glioma using a prognostic signature with 33 immune-related gene pairs","volume":"14","author":"Chen","year":"2021","journal-title":"Int. J. Gen. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.canlet.2015.03.028","article-title":"Novel ALK fusion partners in lung cancer","volume":"362","author":"Iyevleva","year":"2015","journal-title":"Cancer Lett."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.parkreldis.2017.06.004","article-title":"DCTN1-related neurodegeneration: Perry syndrome and beyond","volume":"41","author":"Konno","year":"2017","journal-title":"Park. Relat. Disord."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"7710","DOI":"10.1074\/jbc.M610824200","article-title":"The glucose transporter 4-regulating protein TUG is essential for highly insulin-responsive glucose uptake in 3T3-L1 adipocytes","volume":"282","author":"Yu","year":"2007","journal-title":"J. Biol. Chem."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/path.4158","article-title":"Combining integrated genomics and functional genomics to dissect the biology of a cancer-associated, aberrant transcription factor, the ASPSCR1\u2013TFE3 fusion oncoprotein","volume":"229","author":"Kobos","year":"2013","journal-title":"J. Pathol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1002\/eji.201242655","article-title":"Impairment of adenosine A3 receptor activity disrupts neutrophil migratory capacity and impacts innate immune function in vivo","volume":"42","author":"Butler","year":"2012","journal-title":"Eur. J. Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1038\/sj.bjp.0704352","article-title":"Pharmacological and biochemical characterization of adenosine receptors in the human malignant melanoma A375 cell line","volume":"134","author":"Merighi","year":"2001","journal-title":"Br. J. Pharmacol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1002\/med.21456","article-title":"A3 adenosine receptors as modulators of inflammation: From medicinal chemistry to therapy","volume":"38","author":"Jacobson","year":"2018","journal-title":"Med. Res. Rev."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"4472","DOI":"10.1158\/1078-0432.CCR-03-0651","article-title":"The A3 adenosine receptor is highly expressed in tumor versus normal cells: Potential target for tumor growth inhibition","volume":"10","author":"Madi","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.drudis.2014.02.010","article-title":"Adenosine and inflammation: What\u2019s new on the horizon?","volume":"19","author":"Antonioli","year":"2014","journal-title":"Drug Discov. Today"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1124\/mol.65.3.711","article-title":"Expression of A3 adenosine receptors in human lymphocytes: Up-regulation in T cell activation","volume":"65","author":"Gessi","year":"2004","journal-title":"Mol. Pharmacol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1593\/neo.05334","article-title":"A3 adenosine receptors modulate hypoxia-inducible factor-1a expression in human a375 melanoma cells","volume":"7","author":"Merighi","year":"2005","journal-title":"Neoplasia"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1038\/s41374-020-00516-y","article-title":"ATF-3 expression inhibits melanoma growth by downregulating ERK and AKT pathways","volume":"101","author":"Zu","year":"2021","journal-title":"Lab. Investig."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"657219","DOI":"10.3389\/fcell.2021.657219","article-title":"Transcriptomic analysis identified ARHGAP family as a novel biomarker associated with tumor-promoting immune infiltration and nanomechanical characteristics in bladder cancer","volume":"9","author":"Yang","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.gene.2004.01.025","article-title":"ARHGAP8 is a novel member of the RHOGAP family related to ARHGAP1\/CDC42GAP\/p50RHOGAP: Mutation and expression analyses in colorectal and breast cancers","volume":"336","author":"Johnstone","year":"2004","journal-title":"Gene"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1111\/j.1525-1438.2007.01164.x","article-title":"Microarray analysis of normal cervix, carcinoma in situ, and invasive cervical cancer: Identification of candidate genes in pathogenesis of invasion in cervical cancer","volume":"18","author":"Song","year":"2008","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/42484","article-title":"The putative chaperone calmegin is required for sperm fertility","volume":"387","author":"Ikawa","year":"1997","journal-title":"Nature"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1002\/pros.23654","article-title":"Heritable methylation marks associated with breast and prostate cancer risk","volume":"78","author":"Dowty","year":"2018","journal-title":"Prostate"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1002\/cphy.c160044","article-title":"C1q\/TNF-related protein 3 (CTRP3) function and regulation","volume":"7","author":"Li","year":"2017","journal-title":"Compr. Physiol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.bbaexp.2003.08.013","article-title":"Genomic organization, promoter, amino acid sequence, chromosomal localization, and expression of the human gene for CORS-26 (collagenous repeat-containing sequence of 26-kDa protein)","volume":"1630","author":"Ehling","year":"2003","journal-title":"Biochim. Biophys. Acta BBA-Gene Struct. Expr."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Liu, D., de Souza, J.V., Ahmad, A., and Bronowska, A.K. (2021). Structure, dynamics, and ligand recognition of human-specific CHRFAM7A (Dup\u03b17) nicotinic receptor linked to neuropsychiatric disorders. Int. J. Mol. Sci., 22.","DOI":"10.26434\/chemrxiv.14130518"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"67878","DOI":"10.18632\/oncotarget.18948","article-title":"Expression patterns for nicotinic acetylcholine receptor subunit genes in smoking-related lung cancers","volume":"8","author":"Bordas","year":"2017","journal-title":"Oncotarget"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.4161\/cc.6.15.4556","article-title":"HEXIM1 and the control of transcription elongation: From cancer and inflammation to AIDS and cardiac hypertrophy","volume":"6","author":"Dey","year":"2007","journal-title":"Cell Cycle"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.prp.2015.10.011","article-title":"Role of tumor-associated macrophages in the Hexim1 and TGF\u03b2\/SMAD pathway, and their influence on progression of prostatic adenocarcinoma","volume":"212","author":"Tekindal","year":"2016","journal-title":"Pathol.-Res. Pract."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1002\/gcc.22166","article-title":"Chromosome 19 rearrangements in ovarian carcinomas: Zinc finger genes are particularly targeted","volume":"53","author":"Smebye","year":"2014","journal-title":"Genes Chromosomes Cancer"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.ajhg.2010.06.016","article-title":"Autosomal-recessive early-onset retinitis pigmentosa caused by a mutation in PDE6G, the gene encoding the gamma subunit of rod cGMP phosphodiesterase","volume":"87","author":"Dvir","year":"2010","journal-title":"Am. J. Hum. Genet."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1038\/onc.2012.201","article-title":"Neutrophil chemokines secreted by tumor cells mount a lung antimetastatic response during renal cell carcinoma progression","volume":"32","author":"Posner","year":"2013","journal-title":"Oncogene"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s41423-020-0412-0","article-title":"Neutrophil chemoattractant receptors in health and disease: Double-edged swords","volume":"17","author":"Metzemaekers","year":"2020","journal-title":"Cell Mol. Immunol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"research0035.1","DOI":"10.1186\/gb-2002-3-7-research0035","article-title":"Gene-expression profiling of the response of peripheral blood mononuclear cells and melanoma metastases to systemic IL-2 administration","volume":"3","author":"Panelli","year":"2002","journal-title":"Genome Biol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/ni1088","article-title":"The exogenous pathway for antigen presentation on major histocompatibility complex class II and CD1 molecules","volume":"5","author":"Watts","year":"2004","journal-title":"Nat. Immunol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"10582","DOI":"10.1038\/ncomms10582","article-title":"Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1\/PD-L1 therapy","volume":"7","author":"Johnson","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"484","DOI":"10.6004\/jnccn.2021.0023","article-title":"NCCN guidelines\u00ae insights: Breast cancer, version 4.2021","volume":"19","author":"Gradishar","year":"2021","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1038\/jid.2014.85","article-title":"Dissection of immune gene networks in primary melanoma tumors critical for antitumor surveillance of patients with stage II\u2013III resectable disease","volume":"134","author":"Sivendran","year":"2014","journal-title":"J. Investig. Dermatol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.jaad.2020.03.053","article-title":"Molecular risk prediction in cutaneous melanoma: A meta-analysis of the 31-gene expression profile prognostic test in 1479 patients","volume":"83","author":"Greenhaw","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jaad.2018.07.028","article-title":"Identification of patients at risk of metastasis using a prognostic 31-gene expression profile in subpopulations of melanoma patients with favorable outcomes by standard criteria","volume":"80","author":"Gastman","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1158\/1078-0432.CCR-15-2071","article-title":"PRAME as an independent biomarker for metastasis in uveal melanoma","volume":"22","author":"Field","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1245\/s10434-020-09277-w","article-title":"Characterization of sentinel lymph node immune signatures and implications for risk stratification for adjuvant therapy in melanoma","volume":"28","author":"Farrow","year":"2021","journal-title":"Ann. Surg. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/20\/4973\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:49:49Z","timestamp":1760143789000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/20\/4973"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,11]]},"references-count":58,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["cancers14204973"],"URL":"https:\/\/doi.org\/10.3390\/cancers14204973","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,11]]}}}